Data liberation crusader Hugo Campos landed a win, of sorts, when he took to Twitter to call out Medtronic (NYSE:MDT) CEO Omar Ishrak on the closed nature of the medical device giant’s data.
Minnesota
New Rotation Medical CEO hails from Zimmer, Covidien | Personnel Moves
Minnesota-based orthotics company Rotation Medical appointed Martha Shadan as the new president & CEO.
Vascular Solutions legal updates: We’re ready to fight, CEO says
New Jersey medical device maker Vascular Solutions (NSDQ:VASC) has been fighting patent infringement battles on a couple of fronts, and the company is ready to go the distance to protect its portfolio.
Vascular Solutions posts profits, boosts guidance estimates
Vascular Solutions‘ (NSDQ:VASC) Q2 earnings landed exactly within analyst expectations, ending the company’s long streak of beating the Street.
Despite driving profits up almost 20% and boosting guidance estimates to reflect healthy revenue, Wall Street responded by sending share prices down 0.7% by the end of the day.
St. Jude Medical beats Wall Street on flat Q2 sales
St. Jude Medical (NYSE:STJ) reported flat sales for the 2nd quarter, but still managed to beat out Wall Street’s earnings forecast and raised the bottom end of its earnings forecast for the full year.
Edwards Lifesciences goes after another set of Medtronic patents
Medtronic recalls implantable pacemakers over manufacturing concerns
Medtronic’s insulin pump recall gets FDA’s highest-risk label
The FDA put its highest-risk label, Class I, on a recall of Medtronic’s (NYSE:MDT) Paradigm insulin infusion pumps, which the medtech giant had warned about earlier this year.
Medtronic Canada said last month that it received 2 reports on its Paradigm and Polyfin infusion devices, concerning the over- and under-delivery of insulin therapy.
German court rules for Edwards Lifesciences in patent war over Medtronic’s CoreValve heart valve
Minnetronix nabs neurocritical care company
Medical device maker Minnetronix touted its acquisition of privately held Neurofluidics, a company developing treatment for neurological disorders. The details of the merger were not disclosed.
California-based Neurofluidics became a subsidiary of Minnetronix, which Minnetronix president & CEO Rich Nazarian called a "natural fit."